<table>
<thead>
<tr>
<th>Title</th>
<th>Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Devi, Sapna; Wang, Yilin; Chew, Weng Keong; Lima, Ronald; A-González, Noelia; Mattar, Citra N. Z.; Chong, Shu Zhen; Schlitzer, Andreas; Bakocevic, Nadja; Chew, Samantha; Keeble, Jo L.; Goh, Chi Ching; Li, Jackson L. Y.; Evrard, Maximilien; Malleret, Benoit; Larbi, Anis; Renia, Laurent; Haniffa, Muzlifah; Tan, Suet Mien; Chan, Jerry Kok Yen; Balabanian, Karl; Nagasawa, Takashi; Bachelerie, Françoise; Hidalgo, Andrés; Ginhoux, Florent; Kubes, Paul; Ng, Lai Guan</td>
</tr>
<tr>
<td>Date</td>
<td>2013</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10220/25057">http://hdl.handle.net/10220/25057</a></td>
</tr>
<tr>
<td>Rights</td>
<td>© 2013 Devi et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <a href="http://www.rupress.org/terms">http://www.rupress.org/terms</a>). After six months it is available under a Creative Commons License (Attribution–oncommercial–Share Alike 3.0 Unported license, as described at <a href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</a>).</td>
</tr>
</tbody>
</table>
Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow

Sapna Devi,1 Yilin Wang,1 Weng Keong Chew,1 Ronald Lima,2 Noelia A-González,3 Citra N.Z. Mattar,3 Shu Zhen Chong,1 Andreas Schlitzer,1 Nadja Bakocevic,1 Samantha Chew,1 Jo L. Keeble,1 Chi Ching Goh,1 Jackson L.Y. Li,1 Maximilien Evrard,1 Benoit Mallaret,1 Anis Larbi,1 Laurent Renia,1 Muzlifah Haniffa,1,5 Suet Mien Tan,6 Jerry K.Y. Chan,4,7,8 Karl Balabanian,9 Takashi Nagasawa,10,11 Françoise Bachelerie,9 Andrés Hidalgo,3 Florent Ginhoux,1 Paul Kubes,2 and Lai Guan Ng1

1Singapore Immunology Network (SIgN), A*STAR (Agency for Science, Technology and Research), Biopolis, 138648 Singapore
2Calvin, Phoebe, and Joan Snyder Institute for Infection, Immunity, and Inflammation, University of Calgary, Alberta T2N 1N4, Canada
3Department of Epidemiology, Atherothrombosis and Imaging, Fundación Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
4Experimental Fetal Medicine Group, Yong Loo Lin School of Medicine, National University of Singapore, 119228 Singapore
5Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, England, UK
6School of Biological Sciences, Nanyang Technological University, 637551 Singapore
7Department of Reproductive Medicine, KK Women’s and Children’s Hospital, 229899 Singapore
8Inserm Unite Mixte de Recherche (UMR) 5996, Université Paris-Sud, Laboratory of Excellence in Research on Medication and Innovative Therapeutics, 92140 Clamart, France
9Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, England, UK
10Department of Immunobiology and Hematology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
11Japan Science and Technology Agency (JST), Core Research for Evolutional Science and Technology (CREST), Tokyo 102-0076, Japan

Blood neutrophil homeostasis is essential for successful host defense against invading pathogens. Circulating neutrophil counts are positively regulated by CXCR2 signaling and negatively regulated by the CXCR4–CXCL12 axis. In particular, G-CSF, a known CXCR2 signaler, and plerixafor, a CXCR4 antagonist, have both been shown to correct neutropenia in human patients. G-CSF directly induces neutrophil mobilization from the bone marrow (BM) into the blood, but the mechanisms underlying plerixafor-induced neutrophilia remain poorly defined. Using a combination of intravital multiphoton microscopy, genetically modified mice and novel in vivo homing assays, we demonstrate that G-CSF and plerixafor work through distinct mechanisms. In contrast to G-CSF, CXCR4 inhibition via plerixafor does not result in neutrophil mobilization from the BM. Instead, plerixafor augments the frequency of circulating neutrophils through their release from the marginated pool present in the lung, while simultaneously preventing neutrophil return to the BM. Our study demonstrates for the first time that drastic changes in blood neutrophils can originate from alternative reservoirs other than the BM, while implicating a role for CXCR4–CXCL12 interactions in regulating lung neutrophil margination. Collectively, our data provides valuable insights into the fundamental regulation of neutrophil homeostasis, which may lead to the development of improved treatment regimens for neutropenic patients.

Abbreviations used: LysM, lysozyme; WHIM, Warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis.

© 2013 Devi et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

Neutrophils are produced and stored in the BM, and the control of neutrophil release from BM critically regulates the circulating numbers of these cells in blood. Low numbers of circulating neutrophils (neutropenia) can lead to chronic or even life threatening infections

S. Devi, Y. Wang, and W.K. Chew contributed equally to this paper.

Supplemental Material can be found at: http://jem.rupress.org/content/suppl/2013/09/26/jem.20130056.DC1.html
in human patients if left untreated. Although neutropenia can result from a wide range of underlying causes, including pathogen exposure, pharmacological insults, and genetic factors, the therapeutic options for neutropenic patients are limited.

Numerous studies have shown that CXCR2 and CXCR4 expressed by neutrophils play crucial roles in maintaining neutrophil homeostasis (Semerad et al., 2002; Martin et al., 2003; Suratt et al., 2004; Wengner et al., 2008; Eash et al., 2010; Köhler et al., 2011b). CXCR2 is important for the mobilization of neutrophils from the BM (Suratt et al., 2004; Eash et al., 2010; Köhler et al., 2011b; Mei et al., 2012), whereas CXCR4 promotes neutrophil retention in the BM via interactions with CXCL12 expressed by BM stromal cells (Shirozu et al., 1995; Ponomaryov et al., 2000; Eash et al., 2010). Accordingly, current treatments for neutropenic patients are predominantly directed toward correcting the neutrophil deficiency by mobilizing neutrophils to the circulation while also attempting to treat/control the underlying infection. Granulocyte-CSF (G-CSF) is widely used to treat neutropenic patients in the clinic (Ulich et al., 1988; Lieschke and Burgess, 1992a,b), and previous studies have demonstrated that G-CSF–induced neutrophil mobilization is dependent on CXCR2 signaling (Eash et al., 2010; Köhler et al., 2011b). In contrast, transient blockade of CXCR4 signaling using a small molecule antagonist of CXCR4, plerixafor (AMD 3100), has also been shown to induce neutrophilia (Martin et al., 2003). Inhibition of CXCR4 signaling by plerixafor was effective in correcting neutropenia in a mouse model (Balabanian et al., 2012) and in human patients (Dale et al., 2011; McDermott et al., 2011) with gain-of-function mutations in CXCR4 that confers the warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis (WHIM) syndrome (Hernandez et al., 2003).

RESULTS

Blood neutrophil frequency is rapidly increased after G-CSF or plerixafor treatment

To investigate how G-CSF or CXCR4 inhibition by plerixafor may impact neutrophil activity in the BM, we first established an intravital imaging model that enabled the visualization of these cells within the BM microenvironment of the skull (calvarium; Mazo et al., 1998; Fig. 1 a). Our preliminary dynamic imaging studies showed that the majority of neutrophils in the BM of lysozyme (LysM)–GFP mice (Faust et al., 2000; Fig. S1) were relatively inactive under homeostatic conditions, and neutrophil egress from the BM was a rare event (not depicted). We then visualized steady-state neutrophil distribution relative to BM sinusoids by examining chimeric mice created from irradiated ubiquitous tomato fluorescent protein–expressing (mT/mG) mice (Muzumdar et al., 2007) that were reconstituted with LysM-GFP BM cells, such that their endothelial cells expressed red fluorescent protein and neutrophils expressed green fluorescent protein. Dynamic imaging of these mice confirmed that neutrophils in the narrow space exhibited low baseline motility (~3 µm/min). However, we also observed that perisinusoidal neutrophils displayed an active probing behavior, and that a small fraction of these cells successfully transmigrated from the abluminal surface of the sinusoidal walls into circulation (Fig. 1 b; Video 1).

Having examined the neutrophil activities in the BM under steady-state conditions, we next sought to investigate the BM neutrophil response to promobilization signals by G-CSF and plerixafor treatments. We first determined the appropriate timing for imaging by quantifying the number of circulating neutrophils at various time points after G-CSF or plerixafor administration (Fig. 1 c). Consistent with previous studies, we observed that a single dose of s.c. injection of clinical grade G-CSF (Ulich et al., 1988; Semerad et al., 2002) or plerixafor (Martin et al., 2003) resulted in an increase in the number of circulating neutrophils. Blood neutrophil counts progressively increased over a 4-h period after G-CSF administration, whereas circulating neutrophil numbers peaked at 1–2 h and returned to near basal levels by 4 h after plerixafor treatment. These results suggest that observable changes of neutrophil behavior should occur in the BM within the first
circulation (Video 2). Our tracking analysis showed that neutrophils, at the whole population level, switched from a low motility phenotype (mean velocity, 3.28 µm/min; median velocity, 2.94 µm/min over a 5-min tracking period) under resting conditions to a high motility phenotype that peaked at ~25 min after G-CSF injection (mean velocity, 6.51 µm/min; median velocity, 6.24 µm/min over a 5-min tracking period; Fig. 2 c) and gradually decreased thereafter, but cell migratory activity remained elevated for as long as 2 h after administration. Additionally, we devised a method to quantify endogenous neutrophil egress based on the relative green fluorescent intensity remaining in the marrow space. With this method, we observed a decrease of the green fluorescent intensity in the marrow space in G-CSF–treated mice, indicating neutrophils exiting the BM (Fig. 2 e). This response peaked at ~40 min after G-CSF administration. It is also interesting to note that the GFP intensity recovered to basal levels at later time points after G-CSF treatment. Conceivably, this was a result of migrating neutrophils from other regions of the BM replenishing the depleted marrow space. Consistent with a previous study by Köhler et al. (2011b), we observed that G-CSF–induced 2 h after treatment. We therefore subsequently designed our experiments to image neutrophil responses in the BM from 0 to 2 h after treatment (Fig. 1 d).

**BM neutrophil motility is enhanced by G-CSF**

We next imaged the BM microenvironment in LysM-GFP mice, in which all myelomonocytic cells are tagged with GFP. Neutrophils, however, constitute the major population of these GFP-positive cells (>70%), and they exhibit the highest GFP expression (Fig. S1). Consequently, neutrophils can be easily distinguished from other myelomonocytic cell types based on their high GFP intensity (Chtanova et al., 2008; Peters et al., 2008; Kreisel et al., 2010; Ng et al., 2011; Li et al., 2012). In addition, the BM sinusoids were visualized by intravenous injection of TRITC-dextran (Fig. 2 a). Increased neutrophil motility was detected within ~11 min after a single s.c. injection of G-CSF (mean = 10.63 min ± 0.31 SD, n = 3; Fig. 2 b). These data are in agreement with a previous study of G-CSF effects on neutrophil motility in tibial BM (Köhler et al., 2011b). In mice that received G-CSF, neutrophils were observed to migrate toward the sinusoids before exiting into the blood circulation (Video 2). Our tracking analysis showed that neutrophils, at the whole population level, switched from a low motility phenotype (mean velocity, 3.28 µm/min; median velocity, 2.94 µm/min over a 5-min tracking period) under resting conditions to a high motility phenotype that peaked at ~25 min after G-CSF injection (mean velocity, 6.51 µm/min; median velocity, 6.24 µm/min over a 5-min tracking period; Fig. 2 c) and gradually decreased thereafter, but cell migratory activity remained elevated for as long as 2 h after administration. Additionally, we devised a method to quantify endogenous neutrophil egress based on the relative green fluorescent intensity remaining in the marrow space. With this method, we observed a decrease of the green fluorescent intensity in the marrow space in G-CSF–treated mice, indicating neutrophils exiting the BM (Fig. 2 e). This response peaked at ~40 min after G-CSF administration. It is also interesting to note that the GFP intensity recovered to basal levels at later time points after G-CSF treatment. Conceivably, this was a result of migrating neutrophils from other regions of the BM replenishing the depleted marrow space. Consistent with a previous study by Köhler et al. (2011b), we observed that G-CSF–induced
Neutrophil motility is dependent on CXCR2 (unpublished data), and that the observed increase in cell motility after G-CSF treatment was restricted to neutrophils because BM monocyte migratory activity was not enhanced after G-CSF injection in CX3CR1-GFP mice subjected to the same BM imaging protocol (Fig. 2f).
Neutrophilia induced by CXCR4 inhibition is independent of mobilization from the BM

Interactions between CXCR4 and CXCL12 promote neutrophil retention in the BM and contribute to neutrophil homeostasis (Martin et al., 2003; Suratt et al., 2004; Eash et al., 2010). Accordingly, inhibition of CXCR4 signaling by plerixafor is thought to induce peripheral neutrophilia by increasing neutrophil release from the BM (Martin et al., 2003; Broxmeyer et al., 2005). However, a recent study has suggested that plerixafor treatment can increase blood neutrophil frequency by mobilizing neutrophils from sites other than the BM (Balabanian et al., 2012). To assess whether CXCR4 inhibition-induced neutrophilia is derived from the BM, we first performed dynamic imaging experiments on BM in LysM-GFP mice after plerixafor administration. Contrary to our initial expectations, we observed no change in the migratory behavior of neutrophils after plerixafor treatment (Fig. 2 d). Neutrophils failed to migrate toward the sinusoids and no cells were observed to exit from the BM during the entire imaging period (up to 2 h after drug administration, Fig. 2 e). Despite inducing profound blood neutrophilia, administration of plerixafor had no detectable effect on the migratory behavior of BM neutrophils (Fig. 2, e and g; Video 2). To exclude the possibility that these differential neutrophil responses to G-CSF and plerixafor were specific to the skull BM, we performed additional imaging experiments in tibial BM (Köhler et al., 2011a,b). Neutrophils in tibial BM displayed similar mobilization responses to their skull BM counterparts; G-CSF injection increased cell motility whereas plerixafor treatment did not (unpublished data). These data confirmed that neutrophil mobility in the skull BM displays similar characteristics to BM neutrophils at other sites. Based on these results, we therefore used the model of the skull BM for our subsequent imaging studies, as the skull BM set-up is more robust and less surgically invasive than the tibial model.

Thus, despite exerting different influences on BM neutrophil activity, both G-CSF and plerixafor were capable of
inducing marked increase in circulating neutrophil numbers (Fig. 1 c). To better define the mechanisms that account for this finding, we established two independent experimental models which examine how G-CSF and plerixafor treatment influenced neutrophil egress (BM to blood; experimental model 1) and neutrophil ingress (blood to BM; experimental model 2; Fig. 3 a). We used exogenously transferred GFP+ neutrophils to overcome the technical challenge of tracking endogenous BM neutrophils, as it is difficult to distinguish individual cells within the congested narrow space.

Neutrophil entry and exit from the BM are likely to contribute to the regulation of blood neutrophil counts (Lovás et al., 1996; Suratt et al., 2001; von Vietinghoff and Ley, 2008). Thus, we sought to correlate the rate of neutrophil exit from the BM with the neutrophil frequency in blood. In the egress model, freshly isolated LysM-GFP+ BM cells were adoptively transferred into WT recipient mice and subsequently allowed to reach steady-state localization into the BM for a minimum of 4 h before administration of G-CSF or plerixafor and subsequent BM imaging was performed (Suratt et al., 2001; Fig. 3 b, experimental model 1). G-CSF treatment increased the motility of adoptively transferred GFP+ neutrophils in the skull BM with comparable efficacy to the effects previously observed with endogenous neutrophils in LysM-GFP mice (Fig. 3 c). Administration of G-CSF triggered the redistribution of GFP+ neutrophils toward BM sinusoids and promoted the release of these cells into the circulation (Fig. 3 d; Video 3).

The release of GFP+ neutrophils from the BM peaked between 30 and 50 min after G-CSF administration (Fig. 3 c) and closely mirrored the increase in GFP+ neutrophils detected in the blood (Fig. 3 f). These findings indicated that neutrophil egress from the BM contributed to the number of circulating neutrophils in the blood of G-CSF-treated mice. In contrast, plerixafor treatment did not alter the motility of GFP+ BM neutrophils (Fig. 3 c). The rate of neutrophil egress from the BM in response to plerixafor was comparable to that observed at baseline (Fig. 3, d and e; Videos 4 and 5). However, plerixafor administration still led to a substantial increase of GFP+ neutrophils detected in the circulation (Fig. 3 f). These data suggest that although G-CSF stimulates neutrophil egress from the BM, the rapid increase in circulating neutrophils after CXCR4 inhibition by plerixafor treatment is largely independent of mobilization from this compartment.

CXCR4 does not play a direct active role in the mobilization of neutrophils

To further dissect out the contributions of CXCR2 and CXCR4 in neutrophil mobilization from the BM, we examined how transient inhibition of CXCR4 may influence KC-induced (KC, a CXCR2 ligand) neutrophil mobilization. As shown in Fig. 4 a, we observed that transient CXCR4 inhibition by plerixafor has a synergistic effect on KC-induced neutrophilia when a suboptimal dose of KC was administered. This synergistic effect by plerixafor diminished when higher concentrations were applied, indicating that CXCR2 is the dominant axis for neutrophil egress. Consistent with this observation, our intravital imaging experiments also showed that plerixafor pretreatment augmented KC-induced neutrophil egress from the BM (unpublished data). We also observed that neutrophils which had eventually egressed from the BM were responding from distances further away from the sinusoids (Fig. 4 b and Video 6). Conceivably, blockade of the CXCR4 retention force allowed the neutrophils to become more responsive to KC stimulation. Together, our findings suggest that CXCR4 inhibition does not play a direct active role in neutrophil egress but instead lowers the threshold for mobilizing neutrophils from the BM.

Impaired neutrophil trafficking to the BM after plerixafor treatment increases circulating neutrophils

To visualize neutrophil trafficking to the BM, we infused freshly isolated LysM-GFP+ BM cells into WT recipient mice through the cannulated jugular vein 1 h after treatment with G-CSF or plerixafor (Fig. 5 a, experimental model 2). This approach allowed us to directly visualize the activities of GFP+ neutrophils from the time of first appearance in the microcirculation of the skull BM. In PBS-injected control mice and G-CSF–treated mice, the transferred GFP+ neutrophils were observed to adhere to the luminal surface of the BM sinusoidal walls as early as ~30 min after transfer, followed by transmigration into the BM parenchyma (Fig. 5 b and Video 7). Under these conditions, neutrophil transmigration into the BM compartment reached a plateau within ~2 h of cell transfer (unpublished data). In contrast, GFP+ neutrophil rolling along the vessel walls rarely resulted in recruitment into the BM parenchyma in plerixafor–treated mice (Fig. 5 b and Video 7). This result was confirmed by quantitative image analysis demonstrating a significant reduction in GFP+ neutrophils in BM parenchyma of plerixafor–treated animals compared with either G–CSF–treated mice or PBS–injected control animals (Fig. 5 c). The inhibition of GFP+ neutrophils trafficking
to the BM in plerixafor-treated mice was accompanied by a reciprocal increase in circulating GFP+ neutrophil frequency (Fig. 5 c). To further understand if plerixafor acts directly on the neutrophils, we isolated LysM-GFP+ BM neutrophils from mice pretreated with plerixafor for 1 h before transferring these

treated cells into untreated recipient mice for subsequent imaging (Fig. 5 d). We observed that BM neutrophils from plerixafor-treated mice lacked the ability to traffic back to the BM at 2 h after transfer. This was further validated by flow cytometry experiments, whereby we observed that plerixafor-treated
LysM-GFP+ neutrophils were gradually detected in the BM over a period of 4 h that corresponds to a gradual reduction of these cells in the circulation (Fig. 5 e). Together, these data demonstrate that circulating neutrophil numbers can be increased dramatically by inhibiting homing of these cells to the BM.

**Gain-of-function CXCR4 mutations altered neutrophil mobilization from the BM**

To further understand the role of CXCR4 in neutrophil mobilization, we examined a CXCR4 gain-of-function genetic mouse model, i.e., an animal model for WHIM syndrome (Balabanian et al., 2012). For these experiments, we crossed the WHIM mouse onto LysM-GFP background to directly visualize how the gain-of-function mutations in CXCR4 may influence BM neutrophil activities and how plerixafor may act on these cells. We observed that although G-CSF was able to increase neutrophil motility in the BM of WHIM-LysM-GFP mice in a similar fashion as to the wild-type mice (Fig. 6 a), the mutant neutrophils displaced less as compared with their wild-type counterparts (Fig. 6 b). These results suggest that the CXCR4 gain-of-function mutation renders neutrophils less responsive to G-CSF–mediated egress signals. Consistent with this, quantification of the relative green fluorescent intensity in the BM also showed that the green fluorescent intensity remained relatively constant over the observation period, indicating minimal neutrophil egress in response to G-CSF in the WHIM-LysM-GFP mice (Fig. 6 c). In addition, we also noted that plerixafor did not have an impact on neutrophil motility (not depicted) and egress in the WHIM-LysM-GFP mice (Fig. 6 c).

**Plerixafor inhibits trafficking of CXCR4mut neutrophils to the BM in similar manner as to wild-type neutrophils**

To better define the role of CXCR4 in the retention of neutrophils in the blood, we compared the mobilization ability of the CXCR4 gain-of-function neutrophils versus wild-type neutrophils using the ingress model established earlier (experimental model 2, see Fig. 3 a). This was performed by transferring a 1:1 ratio of selected Ly6G+ cells from the donor BM of both WHIM-LysM-GFP and WT-mT/mG mice into WT recipients pretreated for 1 h with PBS or plerixafor (Fig. 7 a). This method allowed us to easily detect and distinguish the two different fluorescent-tagged neutrophils in the recipient mice via flow cytometry. We observed that the circulating WHIM-LysM-GFP+ neutrophil counts were significantly increased when mice were treated with plerixafor (Fig. 7 b). This increase in circulating neutrophils after plerixafor treatment was also observed with the WT-mT/mG+ neutrophils. In contrast, in the BM of plerixafor–treated mice, we detected a significant reduction of both WHIM-LysM-GFP+ and WT-mT/mG+ LysM-GFP+ neutrophils were gradually detected in the BM over a period of 4 h that corresponds to a gradual reduction of these cells in the circulation (Fig. 5 e). Together, these data demonstrate that circulating neutrophil numbers can be increased dramatically by inhibiting homing of these cells to the BM.

**Gain-of-function CXCR4 mutations altered neutrophil mobilization from the BM**

To further understand the role of CXCR4 in neutrophil mobilization, we examined a CXCR4 gain-of-function genetic mouse model, i.e., an animal model for WHIM syndrome (Balabanian et al., 2012). For these experiments, we crossed the WHIM mouse onto LysM-GFP background to directly visualize how the gain-of-function mutations in CXCR4 may influence BM neutrophil activities and how plerixafor may act on these cells. We observed that although G-CSF was able to increase neutrophil motility in the BM of WHIM-LysM-GFP mice in a similar fashion as to the wild-type mice (Fig. 6 a), the mutant neutrophils displaced less as compared with their wild-type counterparts (Fig. 6 b). These results suggest that the CXCR4 gain-of-function mutation renders neutrophils less responsive to G-CSF–mediated egress signals. Consistent with this, quantification of the relative green fluorescent intensity in the BM also showed that the green fluorescent intensity remained relatively constant over the observation period, indicating minimal neutrophil egress in response to G-CSF in the WHIM-LysM-GFP mice (Fig. 6 c). In addition, we also noted that plerixafor did not have an impact on neutrophil motility (not depicted) and egress in the WHIM-LysM-GFP mice (Fig. 6 c).

**Plerixafor inhibits trafficking of CXCR4mut neutrophils to the BM in similar manner as to wild-type neutrophils**

To better define the role of CXCR4 in the retention of neutrophils in the blood, we compared the mobilization ability of the CXCR4 gain-of-function neutrophils versus wild-type neutrophils using the ingress model established earlier (experimental model 2, see Fig. 3 a). This was performed by transferring a 1:1 ratio of selected Ly6G+ cells from the donor BM of both WHIM-LysM-GFP and WT-mT/mG mice into WT recipients pretreated for 1 h with PBS or plerixafor (Fig. 7 a). This method allowed us to easily detect and distinguish the two different fluorescent-tagged neutrophils in the recipient mice via flow cytometry. We observed that the circulating WHIM-LysM-GFP+ neutrophil counts were significantly increased when mice were treated with plerixafor (Fig. 7 b). This increase in circulating neutrophils after plerixafor treatment was also observed with the WT-mT/mG+ neutrophils. In contrast, in the BM of plerixafor–treated mice, we detected a significant reduction of both WHIM-LysM-GFP+ and WT-mT/mG+
neutrophils. Collectively, this set of data demonstrates that the CXCR4 mutant neutrophils respond similarly to wild-type neutrophils during plerixafor treatment by increasing their retention in blood while preventing neutrophils from trafficking back to the BM.

**Neutrophils are released from the pulmonary circulation in response to plerixafor**

Our data showed that release of neutrophils from the BM compartments does not have a major role in plerixafor-induced neutropenia, pointing to the possibility of alternative neutrophil sources. The lungs accumulate a large pool of transit-delayed (marginated) neutrophils under normal physiological conditions (Doerschk et al., 1987; Lien et al., 1987; Kuebler et al., 1994; Doyle et al., 1997; Kreisel et al., 2010) established by the differentially increased resistance of the pulmonary microvascular bed toward neutrophils. Under physiological state, when dynamic equilibrium is expected (i.e., neutrophil influx equals neutrophil efflux), the reservoir of excess retained neutrophils forms the lung marginated pool. The concentration of neutrophils present in the pulmonary microvascular bed is thought to be 20–60× higher than that present in the large systemic vessels (Lien et al., 1987; Hogg et al., 1994), and the lung has been estimated to hold up to 10–30% of total blood volume (Dock et al., 1961). Thus, the release of neutrophils from the marginated pool in the lung could reasonably be expected to exert a significant impact on circulating neutrophil numbers.

We therefore sought to determine whether G-CSF and plerixafor treatments were capable of triggering the release of marginated neutrophils from the lungs to reenter the circulation. To achieve this, we devised a tandem sampling method of obtaining both arterial blood (carotid) and venous blood (inferior vena cava) while preserving the ventilation and perfusion of the lungs in live mice (Fig. 8a). This approach allowed us to perform differential counts of neutrophils in arterial blood (exiting the lung) and venous blood (entering the lung) while avoiding the potential influence of interposing organs on neutrophil numbers. To validate our tandem sampling method, we used epinephrine as a positive control, which is known to induce rapid demargination of neutrophils from the lungs (Bierman et al., 1952b). This set of experiments showed that indeed, epinephrine treatment increases neutrophil release from the lungs (Fig. 8b).

In plerixafor-treated mice, neutrophil frequency was significantly increased in arterial blood compared with venous blood, which peaked between 2 and 4 h after treatment and returned to basal level after 6 h. In contrast, G-CSF only had an effect on marginated neutrophils in the lung at a later time point (Fig. 8c), and it is conceivable that the mechanism of action is through the down-regulation of CXCR4 expression (Kim et al., 2006). Indeed, we observed that after G-CSF treatment, neutrophils down-regulate CXCR4 expression gradually (unpublished data).

In addition, we have also determined the expression of CXCR4 ligand, CXCL12, in the lung using a CXCL12-GFP mouse (Ara et al., 2003). By flow cytometry, we observed that CXCL12 is expressed by a fraction of endothelial cells, and with immunofluorescence staining of the lungs, we observed that CXCL12 is primarily expressed by capillary endothelial cells (Fig. 8d). Collectively, these data indicate that the CXCR4–CXCL12 interactions contribute to the neutrophil margination and demargination process in the pulmonary circulation.

Having shown the increased release of neutrophils and expression of CXCL12, we next sought to visualize demargination of lung neutrophils in response to CXCR4 inhibition. We analyzed neutrophil activity in the subpleural capillaries of LysM–GFP mice using an intravital lung imaging model described recently (Looney et al., 2011; Fig. 8e). Consistent with previous studies (Lien et al., 1987; Doyle et al., 1997; Kreisel et al., 2010; Looney et al., 2011), we observed a large number of marginated neutrophils within the pulmonary circulation under resting conditions. Administration of plerixafor triggered a reduction in the number of marginated neutrophils in the lungs within 2 h (Fig. 8e). In contrast, the effects of G-CSF on marginated neutrophil numbers were negligible within this time frame, consistent with the neutrophil release data (Fig. 8e and Video 8). As it is technically challenging to preserve the lungs under physiological conditions, each imaging field was imaged for

Figure 7. Neutrophil mobilization patterns of WHIM–LysM–GFP and WT–mT/mG mice. (A) The experimental procedure involved selection of Ly6G+ cells from BM cells isolated from donor WHIM–LysM–GFP and WT–mT/mG mice. Cells were subsequently i.v. transferred in a 1:1 ratio into WT recipient mice pretreated for 1 h s.c. with PBS or plerixafor. 2 h after transfer of fluorescent-tagged cells, blood and perfused femur were collected. (B, Left) The normalized number of circulating fluorescent-tagged neutrophils 2 h after transfer. (B, Right) The normalized number of fluorescent-tagged neutrophils detected in the recipient BM (n = 4–5 per group). A representative set of data were shown from two independent experiments. All data are shown as mean ± SEM. Student’s two-tailed unpaired t test was performed. ***, P < 0.001.
5 min and the data were presented as binary events. To further validate our data, we performed additional experiments to investigate neutrophil margination in the microcirculation of skeletal muscle in mice. This was done by measuring the overall dwell time of neutrophils along muscle capillaries (over the length of 100 µm). This approach allowed us to better examine the dynamic behavior of neutrophil margination in vivo, and we observed that plerixafor reduced neutrophil dwell time within the capillaries of muscle (Fig. 8f and Video 9). This suggests that plerixafor-induced demargination could be a more generalized effect, which occurs throughout the entire vascular system, which may contribute to the rapid rise of neutrophil counts in the blood after plerixafor treatment.
We finally sought to validate our plerixafor finding in a nonhuman primate model (Macaca fascicularis). Longitudinal collection of blood samples is not possible in mice; however, repeated sampling of blood from individual macaques permitted detailed assessment of the neutrophil counts over a 4-h period. 0.5 mg/kg plerixafor was administered s.c. to anesthetized animals and simultaneous blood sampling from the aorta and inferior vena cava was conducted every hour for 4 h thereafter (Fig. 9 a). Analogous to our earlier findings in mice, differential counting of neutrophil frequency in arterial and venous blood samples from two primates revealed an increased number of neutrophils in arterial blood after plerixafor treatment in both animals (Fig. 9 b). Neutrophil release from the lung peaked 2–3 h after plerixafor administration and returned to basal levels by 4 h.

Collectively, the findings from our study are the first to provide direct in vivo evidence demonstrating the ability of CXCR4 inhibition to induce demargination of neutrophils from the lung microvasculature and promote reentry of these cells into the circulation. These data supports the concept that the lung is an important source of neutrophils, which can be mobilized readily into the peripheral blood. Our demonstration that similar neutrophil demargination also occurs in nonhuman primates strongly suggests that our findings also extend to human patients.

**DISCUSSION**

Neutrophils are key mediators of host defense against microbial agents. The distribution of neutrophils between different tissue compartments is a tightly regulated process to maintain stable blood neutrophil counts at resting state, to allow rapid mobilization of neutrophils in response to inflammatory stimuli, and to return to a state of homeostasis after the immune response. Current prevailing views in the scientific community of how blood neutrophil counts are regulated are often rather simplistic; because the BM is the primary site of neutrophil production, any significant increases in circulating neutrophil numbers must therefore be attributed to their release from the BM. This overriding assumption has and may continue to lead to erroneous interpretations of end point studies such as those that relied on the quantification of neutrophil counts in the blood and/or BM as a readout. In the present study, we have used a combination of intravital imaging and in vivo homing assays to study the underlying cellular mechanisms of neutrophil mobilization in a highly compartmentalized manner. We observed that G-CSF and plerixafor work through two distinct cellular mechanisms affecting different compartments: G-CSF exerts its effects by increasing neutrophil mobilization and their release from the BM, which is in agreement with previous studies (Ulich et al., 1988; Semerad et al., 1999; Martin et al., 2003; Eash et al., 2010; Köhler et al., 2011b). However, contrary to the current paradigm, we found that inhibition of CXCR4 did not have a significant impact on BM neutrophil activities. Instead, plerixafor augmented the frequency of circulating neutrophils by simultaneously increasing the number of neutrophils reentering the circulation from the marginalized pool present in the lung, as well as decreasing the number of neutrophils trafficking back to the BM, thereby increasing their retention in the blood.

It is well accepted that G-CSF–induced neutrophilia is a result of increased neutrophil release from the BM. This is established on the basis of G-CSF inducing an increase of neutrophils in the circulation, which is associated with a reciprocal decrease in the number of neutrophils in the BM (Ulich et al., 1988; Semerad et al., 2002; Martin et al., 2003). Indeed, data from our intravital imaging experiments showed that G-CSF increases BM neutrophil motility and redistribution of neutrophils around BM sinusoids, as also described by a recent study (Köhler et al., 2011b). Furthermore, G–CSF–induced neutrophil egress from the BM paralleled the appearance of additional
neutrophils in circulation, demonstrating that these cells are predominantly of BM origin. Of importance, our study has directly demonstrated for the first time that neutrophils that have trafficked back to the BM are able to maintain their capacity to reenter the circulation in response to G-CSF treatment. Thus, the BM may serve as a dynamic reservoir for storing and re-release of circulating neutrophils in response to fluctuating G-CSF levels, leading to implications in our understanding of the role of G-CSF in basic physiology, as G-CSF is produced in response to stress signals. Numerous prior studies have reported a role for CXCR4 in the retention of neutrophils in the BM (Martin et al., 2003; Eash et al., 2009; Petty et al., 2009; Eash et al., 2010). It has therefore been presumed that neutrophilia induced by CXCR4 blockade/plerixafor in both mice and human, results from increased neutrophil release from the BM (Martin et al., 2003; Dale et al., 2011; McDermott et al., 2011; Balabanian et al., 2012). However, there is little direct evidence that plerixafor can act as a BM neutrophil mobilizing agent in vivo. In fact, only a single ex vivo study of the perfused murine femoral BM has reported that plerixafor treatment can increase neutrophil release from this compartment (Martin et al., 2003). Because this study quantified neutrophils only in the femoral vein perfusate after plerixafor administration via the femoral artery, it was unclear whether the increase in neutrophil numbers observed in this model originated from the intravascular pool or the BM. In the current study, our in vivo imaging analyses revealed that plerixafor treatment did not exert a significant impact on BM neutrophil activity in either the endogenous or the cell transfer model. Despite exerting little effect on neutrophil mobilization from the BM, plerixafor still induced a substantial increase in circulating neutrophil numbers, indicating that CXCR4 inhibition may mobilize neutrophils to the blood from additional compartments other than the BM.

It has long been believed that the lung has the capacity to withdraw neutrophils from the blood into the pulmonary microvasculature and can deliver these cells back into the circulation when required (Bierman et al., 1952a). Indeed, neutrophils are rapidly released from the lung into the circulation within only seconds of epinephrine administration, indicating that the lung can serve as an important reservoir of these cells (Bierman et al., 1952b). Our own data revealed that CXCR4 inhibition triggers the release of neutrophils from the lung in both mice and nonhuman primates. The primate data are consistent with our intravaltral lung imaging data obtained in mice, which showed that fewer neutrophils are marginalized in the lung after plerixafor treatment. Thus, in addition to its reported role in mediating the return of senescent neutrophils to the BM (Martin et al., 2003), our study identifies a novel role for CXCR4 in controlling neutrophil margination in the lung. It is tempting to speculate that the regulation of neutrophil removal from circulation by CXCR4 through the margination process is not restricted to the lung but represents a more generalized mechanism of blood neutrophil removal throughout the entire vascular system. This is supported by our findings that plerixafor also reduced neutrophil margination in the capillary beds of skeletal muscle. CXCL12 has been shown to activate integrins LFA-1 and VLA-4 on CD34+ human stem cells (Peled et al., 2000). Given that the integrins play a major role in cell adhesion, it is conceivable that CXCR4 regulates neutrophil margination in lungs by altering integrins expression, and this warrants further investigation. In addition, a previous study demonstrated that plerixafor treatment attenuates allergic lung inflammation (Lukacs et al., 2002). It is important for future studies to investigate the functional importance of CXCR4-mediated neutrophil margination/demargination in lungs, particularly to elucidate how this process may influence neutrophil recruitment into the lung in response to inflammation/infection, as this may have important implications for the clinical use of plerixafor.

Although our work focused extensively on G-CSF and plerixafor as therapeutic agents, if viewed from the perspective of G-CSF as a naturally occurring polypeptide factor and plerixafor as a CXCR4 signaling blocker, our mechanistic investigations have uncovered several startling conclusions about their physiological maintenance in dynamic equilibrium. This may have far-reaching consequences in how we traditionally perceive neutrophil and leukocyte homeostasis. Our current data suggests that the steady increase in neutrophil counts after G-CSF treatment could be mediated by distinct mechanisms that occur in different phases. In the early phase, mobilization of neutrophils from the BM acts as the main mechanism, but in the later phase, there is additional contribution from the demargination of neutrophils. Also, neutrophils in the BM become more responsive to mobilization signals in the later phase. It is important to point out that we are not contesting the value of data from previous works but highlighting that the short-term mechanistic action of the chemokine receptors are more complex and surprising than we would expect from long-term genetic studies. For instance, our cotransfer experiment showed that transient inhibition by plerixafor was able to alter WHIM neutrophil retention in blood and affect BM homing patterns in a similar fashion as wild-type neutrophils. Interestingly, during basal state, we observed a similar proportion of WHIM versus wild-type neutrophils that had trafficked back to the BM. This was unexpected, as prior studies had proposed the cause of abundance accumulation of mature neutrophils (myelokathexis) to be a result of increased neutrophil retention and homing to the BM (Balabanian et al., 2012). A possible explanation for this unexpected finding is the difference in the mechanisms regulating the process of neutrophil homing and egress in WHIM mice. It is conceivable that, under resting conditions, a gain-of-function in CXCR4 plays a functional dominant role in the chemotaxis and chemokinesis of neutrophils in the BM and a much lesser role in the chemotactic homing of neutrophils to the BM. This notion is supported by our imaging data which showed that despite G-CSF causing an increase in motility, WHIM neutrophil egress remained deficient and plerixafor treatment also had minimal effect on BM neutrophil egress. Thus, even in WHIM mice, the consequence of
increased circulating neutrophils with plerixafor treatment appears to be largely dependent on their decreased BM homing. To the best of our knowledge, our work is the first to demonstrate that constitutive CXCR4 signaling, as demonstrated in WHIM mice, promotes neutrophil retention in the BM (defective neutrophil egress) without affecting the efficiency of neutrophil homing (working neutrophil ingress), further highlighting the complexities of CXCR4 in these processes.

The concept of marginated pools as neutrophil reservoirs have been around for a long time, but this fundamentally important concept remains underappreciated. Our study is the first to demonstrate the crucial role of CXCR4–CXCL12 interactions in regulating the pulmonary marginated neutrophil pool, and that drastic change in the circulating neutrophil numbers can be achieved through mobilizing neutrophils from alternative reservoirs other than the BM, and hence demonstrates the importance of studying leukocyte homeostasis in an integrated manner that takes into consideration their compartmentalizations. Of interest, a previous study showed that CXCL12 can act as a vasoconstrictor and that this effect can be inhibited by plerixafor (Mieno et al., 2006). Thus, it is possible that plerixafor may induce changes in the cardiac output, which may be a contributing factor for the demargination of neutrophils in the lung.

From a clinical point of view, we have provided mechanistic insights into how G-CSF and plerixafor, despite their differing influences on neutrophil activity, consequently translate into increases in the number of circulating neutrophils. Our finding here with plerixafor also emphasizes that neutrophil mobilizing agents should be evaluated based on a comprehensive integrated approach, in which the neutrophil pool of different body compartments need to be considered holistically. Our current data shows that plerixafor treatment was able to induce neutrophil release from the lung up to 4 h after administration, and prevented neutrophils from homing back to the BM for up to 3 h. Despite the continued supply of circulating neutrophils from lung demargination, it was thus interesting to note that the overall circulating neutrophil numbers peaked at 1–2 h but returned to near basal levels by 4 h after plerixafor treatment. In contrast, we found that the rate of neutrophil trafficking back to the BM inversely correlated with neutrophil retention in the blood and was the stronger predictor of circulating neutrophil counts. Together, these results suggest that the plerixafor-induced neutrophil retention in the blood might be the primary mechanism responsible for the increased circulating neutrophil numbers detected, and that the demargination of neutrophils from the lung may play an important role only in the early stages after plerixafor treatment. Future studies should focus on examining whether plerixafor induces the presence of distinct populations of circulating neutrophils by changing their homing/margination patterns. Of particular interest, plerixafor is also used as a hematopoietic stem cell (HSC) mobilizing agent (Broxmeyer et al., 2005). In light of our current findings, it will be interesting to determine whether plerixafor-induced HSC mobilization derives solely from the BM. In conclusion, we believe that evidence-based evaluation of drug action will facilitate the design of optimally tailored treatment regimens for neutrophil-related diseases. Further understanding of the biological function of the differential sources of neutrophils will be of particular importance for future studies as these neutrophils may possess distinct homing/adhesion pattern and/or cytokine secretion profile (Mantovani et al., 2011; Pillay et al., 2012).

METHODS AND MATERIALS

Mice. Mice 8–12 wk old were bred in the Biological Resource Centre (BRC) of A*STAR, Singapore, or in the University of Calgary animal facility and were maintained under specific pathogen-free conditions. LysM-GFP mice express enhanced GFP under the LysM promoter and were provided by T. Graf (Centre for Genomic Regulation, Barcelona, Spain; Faust et al., 2000). mT/mG mice (Muzumdar et al., 2007) and CX,CR1 mice (Jung et al., 2000) were obtained from JAX mice. Gain-of-function CXCR4mut mice were generated as previously described (Balabanian et al., 2012). All mouse experiments were performed with the approval of the Institutional Animal Care and Use Committee of the BRC and the University of Calgary Animal Care Committee.

Neutrophil mobilizing reagents. Mice were injected s.c. with 250 µg/kg of recombinant human G-CSF (Roche; Semerad et al., 2002) or 5 mg/kg plerixafor (AMD 3100; Sigma-Aldrich; Broxmeyer et al., 2005; Eash et al., 2010). Control mice were injected s.c. with sterile PBS (Gibco). The dosages for G-CSF and plerixafor administered in mice had been optimized (Broxmeyer et al., 2005) to have comparable effects to doses administered in human clinical studies.

Generation of BM chimeras. Chimeric mice were generated via irradiation and BM transfer as described previously (Hoefl et al., 2012). In brief, 6-wk-old mice were lethally irradiated with two doses of 550 rad spaced 3 h apart. BM cells were harvested from donor mice under sterile conditions and recipient mice were injected retro-orbitally with 5 × 10^6 BM cells within 24 h of irradiation. Recipient mice were maintained under SPF conditions for 8 wk before use in intravital multiphoton microscopy experiments.

Intravital multiphoton imaging of skull BM. Skull BM imaging was performed with minor modifications to published protocols (Mizio et al., 1998; Lo Cefo et al., 2011). Mice were anesthetized with a cocktail of 150 mg/kg ketamine and 10 mg/kg xylazine and immobilized on a customized stage. A heating pad affixed to the stage was used to maintain animal temperature at 37°C. A small area of skin on the skull was removed to expose the skull BM. The exposed skull was superfused with sterile PBS, covered with a glass coverslip, and visualized with a LaVision TriM Scope II microscope (LaVision BioTec), equipped with a 20 × 1.4 NA WD objective lens and a Coherent Chameleon pulsed infrared laser. Experiments were performed at 880 nm excitation unless otherwise specified. Images were acquired using a 4-µm z-step size with an approximate z-depth of 50 µm. Image stacks were acquired every 20 s over a 2-h imaging period. To label blood vessels in vivo, mice were retro-orbitally injected with 4 µg TRITC-conjugated 155-kD dextran (Sigma-Aldrich) in 200 µl saline (Li et al., 2012). Imaging of the tibial BM was performed as previously described (Köhler et al., 2011a).

Image analysis. Images were transformed into time series movies and analyzed using IMARIS image analysis software (Bitplane). Tracking of cell motility in three dimensions was performed in a semiautomated manner as described previously (Ng et al., 2008, 2011). The mean/median and instantaneous migration velocities were typically obtained from 121 consecutive frames of video. To quantitate the endogenous neutrophil egress, the relative GFP fluorescence intensity was determined in specified regions of the marrow space using the surface function in surpass mode in IMARIS. For the analysis of experimental model 1 (neutrophil egress), the number of transmigrated GFP+ cells was quantified manually.
Murine BM cell isolation and transfer. The right femur of LysM-GFP mice were removed and the femoral BM was harvested by flushing with ~10 ml PBS containing 3% FCS. RBCs were lysed using commercial-grade RBC lysis buffer (E Bioscience) and the remaining cells were resuspended in sterile PBS. In some experiments, 5 × 10^5 Lys-M-GFP + BM cells were delivered retro-orbitally or by catheterization and infusion via the left jugular vein. In another set of experiments, both the femur and tibia of WHIM-LysM-GFP and WT-mT/mG mice were removed and BM cells were harvested as described earlier. This was then followed by negatively selecting Ly6G+ cells from BM cells with the EasySep mouse neutrophil enrichment kit (STEMCELL Technologies, Inc.). 2.5 × 10^6 neutrophils from WHIM-LysM-GFP + and WT-mT/mG + cells were subsequently mixed and delivered retro-orbitally.

Measurement of neutrophil numbers by flow cytometry. Cells isolated from the femur and/or blood was collected for analysis by flow cytometry. Samples were subjected to RBC lysis followed by incubation with blocking buffer (3% FCS and 5% rat serum in PBS) for 10 min. Cells were stained with the following antibodies: PE-conjugated CD115 (clone AFS98), PerCP-Cy5.5-conjugated CD11b (clone M1/70), and APC-Cy7-conjugated CD45 (clone 30-F11) from BioLegend; and APC-conjugated Ly-6G (clone 1A8) from BioLegend. Cells were stained with DAPI (Invitrogen) to assess cell viability and CountBright absolute counting beads (Invitrogen) were added before acquisition to enable calculation of absolute cell numbers. All samples were acquired using a FACSCanto II flow cytometer (BD) equipped with FACSDiva software. Data analysis was performed using FlowJo software (Tree Star).

Assessment of circulating neutrophils at different sites of blood collection. Mice were anesthetized with a cocktail of 150 mg/kg ketamine and 10 mg/kg xylazine and placed on a heating pad at 37°C. The right carotid artery was cannulated using a previously described method (Duyverman et al., 2012). In brief, a midline incision was made on the neck and the glands were separated sideways to expose the trachea before the surrounding tissues were cleared to expose the underlying carotid artery. A polyethylene 10 tubing (inner diameter: 0.28 mm; outer diameter: 0.61 mm) was drawn to reduce the diameter at the tip for cannulation. A microvascular clamp was applied to the artery before insertion of the EDTA-filled tubing. The cannula was secured with a surgical suture and then the clamp was released to allow blood collection into an Eppendorf tube. Blood was then immediately withdrawn from the inferior vena cava using a 26G needle attached to a syringe prefilled with EDTA. Blood samples from different sites were prepared for FACS analysis as described earlier. In experiments using epinephrine as a positive stimulus, blood was collected from the anterior vena cava using a 26G needle attached to a syringe prefilled with 50 µg Evan’s blue dye to label blood vessels in vivo. The blood was subsequently released into a custom-made stage and a heat pad was used to maintain the body temperature. To expose the skeletal muscle for imaging, a small area of skin was removed and loose dermal connective tissue was cleared to allow better visualization of the intact skeletal muscle vasculature. The exposed area was superfused with sterile PBS and sealed with a coverslip, with additional heating provided for the exposed muscle at 37°C. Experiments were performed at 950 nm excitation and images were acquired using a 5-µm z-step size with an approximate z-depth of 120 µm. Image stacks were acquired every 30 s over a 1-h imaging period.

Determination of circulating neutrophils in nonhuman primates. All experiments on adult female Macaca fascicularis nonhuman primates (2.5 kg and 3.2 kg, respectively) were performed at the SingHealth Experimental Medicine Centre (accredited by the Association for Assessment and Accreditation of Laboratory Animal Care) under approval #2012/SHS/692 from the Institutional Animal Care and Use Committee of Singapore. Mid-line laparotomy was performed under general anesthesia, and the retro-peritoneum was reflected along the mesenteric insertion. The descending abdominal aorta and inferior vena cava were identified and ~1 ml blood was collected from each using a 25G needle 10 min before s.c. administration of 0.5 mg/kg plerixafor and at hourly intervals thereafter. Blood leukocyte counts were performed using a Hematology Analyzer (Beckman-Coulter).

Statistical analysis. Statistical analyses were conducted using Student’s t test (normally distributed data) or one-way analysis of variance (ANOVA). P-values <0.05 were considered significant.

Online supplemental material. Fig. S1 shows assessment of leukocyte GFP expression in the BM of LysM-GFP mice. Video 1 shows neutrophil behavior in the skull BM. Video 2 shows dynamic behavior of neutrophil in the BM in response to G-CSF or plerixafor treatment. Video 3 shows that G-CSF increases neutrophil egress from the BM. Video 4 shows that plerixafor does not increase the number of neutrophil egress from the BM. Video 5 shows basal levels of neutrophil egress from the BM. Video 6 shows that plerixafor pretreatment augments KC-induced neutrophil egress from the BM. Video 7 shows neutrophil trafficking to the BM. Video 8 shows intravital imaging of neutrophils in the lung. Video 9 shows intravital imaging of neutrophils in skeletal muscle. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20130056/DC1.

We wish to thank Drs. Matthew Krummel and Sebastian Peck and the UCSF Biological Imaging Development Center for assistance in intravital lung preparation. We wish...


published September 30, 2013

Copyright © 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Neutrophil mobilization to the blood | Devi et al.


